These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 26465961)
1. Bullous Pemphigoid Associated With Linagliptin Treatment. Haber R; Fayad AM; Stephan F; Obeid G; Tomb R JAMA Dermatol; 2016 Feb; 152(2):224-6. PubMed ID: 26465961 [No Abstract] [Full Text] [Related]
2. Linagliptin-associated bullous pemphigoid treated with rituximab. Mani H; Safo P; Onitilo AA BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31570343 [TBL] [Abstract][Full Text] [Related]
3. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history. García-Gil MF; Lezcano Biosca V; García García M; Monte Serrano J; Aldea Manrique B Postgrad Med J; 2021 Jan; 97(1143):51-52. PubMed ID: 32198232 [No Abstract] [Full Text] [Related]
4. Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin. Mendonça FM; Martín-Gutierrez FJ; Ríos-Martín JJ; Camacho-Martinez F Dermatology; 2016; 232(2):249-53. PubMed ID: 26820308 [TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases. Jha A; Misra A; Gupta R; Ghosh A; Tyagi K; Dutta K; Arora B; Durani S Diabetes Metab Syndr; 2020; 14(3):213-216. PubMed ID: 32172176 [TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01. Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957 [TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading. Takama H; Yoshida M; Izumi K; Yanagishita T; Muto J; Ohshima Y; Nishie W; Shimizu H; Akiyama M; Watanabe D Acta Derm Venereol; 2018 Nov; 98(10):983-984. PubMed ID: 30085319 [No Abstract] [Full Text] [Related]
8. Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology. Murakami T; Yabe D; Inagaki N J Diabetes Investig; 2019 Sep; 10(5):1168-1170. PubMed ID: 30989811 [TBL] [Abstract][Full Text] [Related]
9. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Aouidad I; Fite C; Marinho E; Deschamps L; Crickx B; Descamps V JAMA Dermatol; 2013 Feb; 149(2):243-5. PubMed ID: 23426497 [No Abstract] [Full Text] [Related]
10. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea. Lee H; Chung HJ; Pawar A; Patorno E; Kim DH JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcome and safety profile of rituximab for the treatment of Dipeptidyl peptidase 4 inhibitors-induced Bullous pemphigoid. Nieto-Benito LM; Bergón-Sendín M; Pulido-Pérez A; Suárez-Fernández RM Exp Dermatol; 2022 Apr; 31(4):641-642. PubMed ID: 34695279 [No Abstract] [Full Text] [Related]
12. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. Kridin K; Bergman R JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931 [TBL] [Abstract][Full Text] [Related]
13. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes. Guliani A; Bishnoi A; Aggarwal D; Parsad D Postgrad Med J; 2018 Nov; 94(1117):662-663. PubMed ID: 30317183 [No Abstract] [Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Phan K; Charlton O; Smith SD Australas J Dermatol; 2020 Feb; 61(1):e15-e21. PubMed ID: 31215644 [TBL] [Abstract][Full Text] [Related]
15. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases. Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234 [TBL] [Abstract][Full Text] [Related]
16. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature. Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H Front Immunol; 2018; 9():542. PubMed ID: 29706950 [TBL] [Abstract][Full Text] [Related]